McKesson (NYSE:MCK – Get Rating) is set to issue its quarterly earnings data after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of $6.06 per share for the quarter. McKesson has set its FY22 guidance at $23.55-23.95 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.
McKesson (NYSE:MCK – Get Rating) last posted its earnings results on Wednesday, February 2nd. The company reported $6.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $5.38 by $0.77. The business had revenue of $68.61 billion for the quarter, compared to analyst estimates of $66.63 billion. McKesson had a net margin of 0.55% and a negative return on equity of 1,931.18%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.60 EPS. On average, analysts expect McKesson to post $24 EPS for the current fiscal year and $23 EPS for the next fiscal year.
NYSE:MCK opened at $317.85 on Thursday. McKesson has a twelve month low of $180.41 and a twelve month high of $335.60. The firm has a market capitalization of $47.61 billion, a price-to-earnings ratio of 35.75, a PEG ratio of 1.22 and a beta of 0.72. The firm’s fifty day simple moving average is $299.44 and its 200 day simple moving average is $257.53.
In other McKesson news, EVP Tracy Faber sold 2,034 shares of the business’s stock in a transaction dated Monday, February 7th. The shares were sold at an average price of $265.23, for a total transaction of $539,477.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 5,438 shares of the business’s stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $323.25, for a total transaction of $1,757,833.50. The disclosure for this sale can be found here. Insiders sold a total of 10,795 shares of company stock valued at $3,329,690 over the last ninety days. Company insiders own 0.28% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Synovus Financial Corp boosted its stake in McKesson by 3.8% during the 4th quarter. Synovus Financial Corp now owns 2,107 shares of the company’s stock valued at $524,000 after purchasing an additional 77 shares during the period. Horizon Investments LLC lifted its stake in shares of McKesson by 8.7% in the 4th quarter. Horizon Investments LLC now owns 1,167 shares of the company’s stock worth $290,000 after acquiring an additional 93 shares during the period. Penserra Capital Management LLC lifted its stake in shares of McKesson by 19.7% in the 4th quarter. Penserra Capital Management LLC now owns 692 shares of the company’s stock worth $172,000 after acquiring an additional 114 shares during the period. EP Wealth Advisors LLC lifted its stake in shares of McKesson by 1.5% in the 4th quarter. EP Wealth Advisors LLC now owns 8,175 shares of the company’s stock worth $2,032,000 after acquiring an additional 122 shares during the period. Finally, KB Financial Partners LLC acquired a new stake in shares of McKesson in the 4th quarter worth approximately $37,000. 86.01% of the stock is owned by hedge funds and other institutional investors.
About McKesson (Get Rating)
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
- Get a free copy of the StockNews.com research report on McKesson (MCK)
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.